Mika, a HealthTech company, has secured a coveted spot in the inaugural cohort of the US government's "CancerX Accelerator" program, making it the sole German participant. Launched under the "Cancer Moonshot" initiative by the White House, CancerX aims to halve the death rate from cancer within the next 25 years while enhancing the quality of life for patients and their families.
Selected from over 100 applicants through a rigorous three-round evaluation process, Mika impressed notable sponsors including Debiopharm, Reveal HealthTech, UC Davis Health, Atrium, Dell Technologies, Intel, AstraZeneca, AWS, and Oncology Ventures. This recognition underscores Mika's commitment to advancing cancer care and marks a significant milestone as they prepare for entry into the US market.
As part of the program, Mika and fellow participants will collaborate with sponsors over four months, leveraging mentorship and engaging with members across the healthcare ecosystem to refine and validate their solutions. The CancerX Accelerator aims to foster long-term partnerships and sustainable growth strategies, with the ultimate goal of expediting access to digital therapeutics in oncology to combat cancer effectively.
Click here to read the original news story.